<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>COVID-19: Cutaneous manifestations and issues related to dermatologic care</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">COVID-19: Cutaneous manifestations and issues related to dermatologic care</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">COVID-19: Cutaneous manifestations and issues related to dermatologic care</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven R Feldman, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Esther E Freeman, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey Callen, MD, FACP, FAAD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 13, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2164118430"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), raises many critical issues in dermatology and dermatologic care. Addressing these issues is necessary, yet also challenging, because there are few direct data on which to base recommendations [<a href="#rid1">1</a>].</p><p>This topic will discuss issues related to dermatologic care during the COVID-19 pandemic. Other relevant aspects of SARS-CoV-2 infection and patient management are discussed in detail separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/126981.html" rel="external">"COVID-19: Epidemiology, virology, and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128404.html" rel="external">"COVID-19: Diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease"</a>.)</p><p></p><p class="headingAnchor" id="H2979176773"><span class="h1">CUTANEOUS MANIFESTATIONS OF COVID-19</span></p><p class="headingAnchor" id="H1535224896"><span class="h2">Frequency</span><span class="headingEndMark"> — </span>Studies from around the world have identified a range of potential dermatologic manifestations of COVID-19 [<a href="#rid2">2-8</a>]. Reports of the prevalence of cutaneous manifestations in patients with COVID-19 vary, ranging from less than 1 percent to more than 20 percent of patients [<a href="#rid9">9-17</a>]. Data from two large, population-based studies suggest frequencies of cutaneous manifestations (before the Delta variant) in the range of 10 to 13 percent [<a href="#rid13">13,14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a United Kingdom study during the initial wave of COVID in 2020 that matched self-reported symptoms collected through a COVID symptom application with polymerase chain reaction (PCR) test results, the presence of self-reported body rash or acral rash was associated with a positive SARS-CoV-2 test (odds ratio [OR] 1.67, 95% CI 1.42-1.97) [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Subsequently, a second prospective study from the same group assessed rash, burning rash, erythematopapular rash, urticarial rash, and unusual hair loss during the Delta and Omicron waves of the pandemic [<a href="#rid15">15</a>]. Compared with individuals who tested negative, the prevalence of reported cutaneous manifestations was higher among individuals who tested positive for SARS-CoV-2 during the Delta wave (18 versus 9 percent; OR 2.29, 95% CI 2.22-2.36) and, less markedly, during the Omicron wave (11 versus 10 percent; OR 1.29, 95% CI 1.26-1.33). Similar to other manifestations of COVID-19, the prevalence and characteristics of skin findings and their association with a positive test for SARS-CoV-2 might differ among COVID-19 variants [<a href="#rid15">15</a>].</p><p></p><p class="headingAnchor" id="H4102820119"><span class="h2">Clinical presentations</span><span class="headingEndMark"> — </span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aad.org%2Fmember%2Fpractice%2Fcoronavirus%2Fregistry&amp;token=T2Iknvk5inwR74f3CzLleF%2FoISStRBNhsj07Fc71SdL9TgAyDtQpWYF7%2FNMqq3orBDhYnx%2Be%2B%2Bl0tgh0gIIJCQ%3D%3D&amp;TOPIC_ID=127978" target="_blank">The American Academy of Dermatology's COVID-19 Registry</a>, a collaboration between the American Academy of Dermatology and the International League of Dermatologic Societies, is attempting to collate cases and better define the cutaneous manifestations of COVID-19 [<a href="#rid18">18</a>] (see <a class="local">'Registries'</a> below). In a 2020 analysis of 171 patients with laboratory-confirmed COVID-19 and cutaneous manifestations from the registry, the most commonly reported cutaneous manifestations were morbilliform rash (22 percent), pernio-like acral lesions (18 percent), urticaria (16 percent), macular erythema (13 percent), vesicular eruption (11 percent), papulosquamous eruption (9.9 percent), and retiform purpura (6.4 percent) [<a href="#rid19">19</a>]. Fever and cough were reported in approximately 60 percent of cases.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exanthematous (morbilliform) rash</strong> – In several case series, a morbilliform rash predominantly involving the trunk has been reported as the most common cutaneous manifestation of COVID-19 [<a href="#rid2">2,3,10,19-21</a>]. The rash has been noted either at the disease onset or, more frequently, after hospital discharge or recovery [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pernio (chilblain)-like acral lesions</strong> – Pernio (chilblain)-like lesions of acral surfaces ("COVID toes") present as erythematous-violaceous or purpuric macules on fingers, elbows, toes, and the lateral aspect of the feet, with or without accompanying edema and pruritus  (<a class="graphic graphic_picture graphicRef128273 graphicRef129621" href="/z/d/graphic/128273.html" rel="external">picture 1A-B</a>) (see  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Incidence</strong> – Pernio-like lesions have been increasingly reported across the age spectrum during the COVID-19 pandemic, with most cases occurring among adolescents and young adults. In a northern California study, the incidence of chilblains increased during the pandemic (April 2020 to December 2020) compared with the prepandemic period (April 2016 to December 2019), from 5.2 per 100,000 person-years (95% CI 4.8-5.6) to 28.6 per 100,000 person-years (95% CI 26.8-30.4) [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Association with SARS-CoV-2 infection</strong> – During the pandemic, pernio-like lesions have been reported in patients with or without confirmed COVID-19 or a history of contact with patients with confirmed COVID-19 and in the absence of documented cold exposure or underlying conditions associated with pernio [<a href="#rid2">2-4,19,22-30</a>]. Among individuals with pernio-like lesions, SARS-CoV-2 PCR positivity rates ranged from 3 to 7 percent during the wild-type wave of the pandemic but decreased during the subsequent waves of SARS-CoV-2 variants. The association between chilblains and COVID-19 remains controversial.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Among users of the COVID Symptom Study application in the United Kingdom who were tested with SARS-CoV-2 PCR during the wild-type wave of the pandemic, the rate of self-reported acral rash was higher among those who tested positive compared with those who tested negative (3.1 versus 1.8 percent; OR 1.74, 95% CI 1.33-2.28) [<a href="#rid13">13</a>]. During subsequent waves with the SARS-CoV-2 Delta and Omicron variants, the frequency of self-reported acral rash among individuals who tested positive decreased to 1.1 and 0.7 percent, respectively. The association of acral rash with SARS-CoV-2 PCR test positivity was statistically significant for Delta (OR 1.79, 95% CI 1.60-2.01) but not for Omicron (OR 0.96, 95% CI 0.86-1.07) [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a French series of 311 patients (median age 26 years) with acral manifestations seen between March 2020 and May 2020, 150 patients (49 patients with symptoms suspicious for COVID-19) underwent nasopharyngeal swab reverse transcription (RT)-PCR and/or serology for SARS-CoV-2 [<a href="#rid31">31</a>]. Five of 75 patients were positive for SARS-CoV-2 serology, and 7 of 121 patients were positive for SARS-CoV-2 RT-PCR. Overall, 10 of 170 patients (7 percent) had confirmed COVID-19.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In the American Academy of Dermatology/International League of Dermatologic Societies registry study, of 318 cases from eight countries, 14 of these cases were PCR positive (4.4 percent) [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a large, retrospective, cohort study conducted within a health care system in northern California that included 780 patients diagnosed with chilblains between April 2020 and December 2020, of 456 patients who underwent PCR testing for SARS-CoV-2, 17 patients (3.7 percent) were positive [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent2">Some authors have noted that a negative PCR would be expected in patients who develop pernio-like lesions 7 to 21 days after initial SARS-CoV-2 infection. Therefore, additional analysis of the antibody profiles of these patients has been evaluated [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent2">Positive serology rates of 1 to 17 percent (mainly for SARS-CoV-2 immunoglobulin G [IgG] and immunoglobulin M [IgM]) have been reported in a limited number of patients with pernio-like lesions and negative PCR for SARS-CoV-2 [<a href="#rid4">4,22,33,34</a>]. In most cases, serology was performed only at one point in time.</p><p></p><p class="bulletIndent2">Of note, in some series of patients, specific immunoglobulin A (IgA) antibodies were detected more frequently than IgG [<a href="#rid34">34,35</a>]:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a subset of 97 patients from a series of 780 patients with chilblains reported during the pandemic, single time point IgG positivity rate was 1 percent [<a href="#rid22">22</a>]. IgM and IgA were not tested [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a French series of 40 consecutive patients with chilblain-like lesions, COVID-19 serology was positive in 12 patients, of whom 7 (17.5 percent) had only IgA and 5 (12.5 percent) had IgG [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In an Italian series of 30 children with pernio-like lesions, of whom 17 were retested at a five- to seven-week interval, the overall positivity rate was 17 percent for IgG and 53 percent for IgA [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a United States small cohort of 21 patients with chilblains diagnosed during the first wave of the pandemic, only two cases (9 percent) had PCR test-confirmed SARS-CoV-2 infection; positive serology for IgG, IgA, and IgM antibodies against S, receptor binding domain, and nucleocapsid antigens; and evidence of antigen-specific T cell responses to SARS-CoV-2 [<a href="#rid36">36</a>]. Serology and T cell response were negative in the other 19 patients with chilblains.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>In a study of 50 patients with chilblain-like lesions seen during the first wave of the pandemic, PCR testing for SARS-CoV-2 as well as serology for IgG and IgA were negative in all patients [<a href="#rid37">37</a>]. Compared with patients with seasonal chilblains seen before the pandemic, chilblain-like lesions had similar histopathologic and immunohistochemical features, as well as immune transcriptomic signature, with upregulation of type I and II interferon pathways, T helper 1 (Th1) cell polarization, cytotoxicity markers, and natural killer signaling.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical presentation and course</strong> – The majority of patients with pernio-like lesions and confirmed or suspected SARS-CoV-2 infection were asymptomatic or had mild symptoms compatible with COVID-19, with very rare reports of severe COVID-19 in patients with pernio-like lesions [<a href="#rid2">2,4,35,38,39</a>]. In the American Academy of Dermatology/International League of Dermatologic Societies registry study, 55 percent of patients overall were otherwise asymptomatic, and 98 percent of patients in the study were treated in the outpatient setting alone [<a href="#rid4">4</a>]. This finding held true when restricted to laboratory-confirmed cases only, with 78 percent remaining in the outpatient setting.</p><p></p><p class="bulletIndent2">In patients with confirmed or suspected SARS-CoV-2 infection, pernio lesions started one to four weeks after the onset of COVID-19 symptoms, suggesting a postviral or delayed-onset process. In the American Academy of Dermatology/International League of Dermatologic Societies registry, 80 of 318 cases with pernio-like lesions developed lesions after the onset of other COVID-19 symptoms [<a href="#rid4">4</a>]. In some cases, lesions appeared while patients were still PCR positive for the virus [<a href="#rid4">4,30</a>].</p><p></p><p class="bulletIndent2">Resolution usually occurred in two to eight weeks. A prolonged course of more than 60 days has been reported in some patients ("long haulers") [<a href="#rid40">40</a>]. Additionally, some patients have developed recurrence of pernio, likely triggered by cold, during the following fall-winter season [<a href="#rid41">41,42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Potential pathogenetic mechanisms</strong> – Proposed mechanisms for the development of pernio-like lesions during the pandemic include a reaction to the immune response to the virus and pandemic-related lifestyle changes that may increase the risk for pernio. As an example, in a large, cohort study that included 780 patients with pernio seen during the pandemic, 94 percent reported not wearing shoes at home [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent2">Examination of biopsied pernio-like lesions demonstrates a primarily inflammatory process, with histopathologic and direct immunofluorescence findings similar to those seen in idiopathic and autoimmune-related pernio [<a href="#rid3">3,26,28,43-46</a>]. (See  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)", section on 'Skin biopsy'</a>.)</p><p></p><p class="bulletIndent2">These inflammatory changes have been hypothesized to be associated with enhanced interferon-alpha responses to the virus and are, at times, associated with an IgA antibody response to the virus [<a href="#rid35">35,40,47</a>].</p><p></p><p class="bulletIndent2">A French study demonstrated increased in vitro production of interferon-alpha from stimulated peripheral blood T cells in patients with pernio compared with patients with PCR-positive, moderate to severe COVID-19 without pernio, suggesting that a robust, innate immune response may lead to rapid control of the virus in these patients and could, at least in part, explain the relatively mild disease course and low level of antibody production [<a href="#rid47">47</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Management</strong> – There are no treatment guidelines for COVID-19-associated, pernio-like lesions of the feet or hands. However, clinical experience suggests that high-potency topical corticosteroids may be helpful if the lesions are causing discomfort. (See  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)", section on 'Management'</a>.)</p><p></p><p class="bulletIndent2">Although PCR positivity has been found infrequently in patients with pernio during the COVID-19 pandemic and not all cases are necessarily related to COVID-19, it may be prudent that patients presenting with new-onset, pernio-like lesions that have no other clear cause be tested for SARS-CoV-2 PCR within seven days of the onset of pernio lesions [<a href="#rid32">32,48-50</a>]. For patients who have had these lesions for &gt;4 weeks, IgM and IgG antibody testing can be considered, following local guidelines and depending on the quality of available tests, acknowledging that many of these patients may only make transient antibody responses or IgA responses that are not currently being tested in commercial laboratories. A positive serology could rule out other causes of pernio that might need additional work-up. Work-up of other causes of pernio is discussed in greater detail separately [<a href="#rid2">2,4,35</a>]. (See  <a class="medical medical_review" href="/z/d/html/13758.html" rel="external">"Pernio (chilblains)", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Livedo reticularis-like </strong>– Livedo reticularis-like vascular lesions have been reported in a few patients with COVID-19 [<a href="#rid19">19,24,51-55</a>]. In a series of 171 laboratory-confirmed cases, these vascular lesions were noted in 5.3 and 2.3 percent of patients, respectively [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fixed livedo racemosa/retiform purpura/necrotic vascular lesions</strong> – Retiform purpura and necrotic vascular lesions seem to be associated with severe COVID-19  (<a class="graphic graphic_picture graphicRef129622 graphicRef129623" href="/z/d/graphic/129622.html" rel="external">picture 2A-B</a>) [<a href="#rid19">19,24,56,57</a>]. In a series of 11 patients with retiform purpura and laboratory confirmed COVID-19, all were hospitalized and nine had acute respiratory distress syndrome [<a href="#rid19">19</a>]. In three patients with SARS-CoV-2 infection and severe respiratory failure who had retiform purpura or livedo racemosa, histologic and immunohistochemistry studies of skin biopsies revealed a pattern of complement-mediated microvascular injury in both involved and normally appearing skin [<a href="#rid56">56</a>]. Histopathologic findings of thrombotic vasculopathy and/or laboratory coagulation alterations have also been demonstrated in patients with severe COVID-19 and acral ischemic lesions [<a href="#rid43">43,57</a>]. (See  <a class="medical medical_review" href="/z/d/html/16556.html" rel="external">"Approach to the patient with retiform (angulated) purpura"</a> and  <a class="medical medical_review" href="/z/d/html/4684.html" rel="external">"Livedoid vasculopathy"</a> and  <a class="medical medical_review" href="/z/d/html/127926.html" rel="external">"COVID-19: Hypercoagulability"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urticaria</strong> – Acute urticaria with or without concomitant fever has been reported as a presenting sign of COVID-19 infection [<a href="#rid2">2,3,10,19,24,58</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vesicular (varicella-like) eruptions</strong> – There are several reports describing a vesicular-pustular, varicella-like eruption associated with COVID-19 [<a href="#rid2">2,24,59,60</a>]. In a series of 24 patients, an eruption of small papules, vesicles, and pustules appeared 4 to 30 days after the onset of COVID symptoms and resolved in a median of 10 days [<a href="#rid61">61</a>]. A real-time PCR for SARS-CoV-2 from vesicle content performed in four patients yielded negative results. Seventeen of 24 patients were not taking any medications, ruling out a drug reaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Multisystem inflammatory syndrome in children (MIS-C) </strong>– An erythematous, polymorphic rash, erythema and/or firm induration of hands and feet, oral mucositis, and conjunctivitis, along with systemic, laboratory, and imaging findings of atypical, severe Kawasaki disease, were initially described in a cohort of 10 Italian children during the COVID-19 pandemic [<a href="#rid62">62</a>]. Similar cases have been reported in the United Kingdom [<a href="#rid63">63</a>], the United States [<a href="#rid64">64</a>], and other countries. Case definitions for MIS-C have been proposed by the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.who.int%2Fpublications%2Fi%2Fitem%2Fmultisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19&amp;token=P5RB8Rt1%2FWHHQGPD3OxaQxgtqpk%2B2cYoCF9tEqocWe4if3sxD8BllA8pdJjPcAN0okwcqAvilY8PBq4NFFpncLZy4F2raBJuS8EEgDVyNOhZthRxLvmKaY2DTkNe76gHdP9LEmcF47LcRtl%2FlDYgfg%3D%3D&amp;TOPIC_ID=127978" target="_blank">World Health Organization</a> and the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Femergency.cdc.gov%2Fhan%2F2020%2Fhan00432.asp&amp;token=%2FXpciKoGXD%2FNBcI56myByC8j%2FgwUrJ%2BP4RmkkZzri9POD%2Fc%2Fe0m3CBRgdpjC7JP8KaGrX5U99bUm51CUnp9LMg%3D%3D&amp;TOPIC_ID=127978" target="_blank">United States Centers for Disease Control and Prevention</a>. (See  <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p></p><p>Less frequently reported dermatologic manifestations include papulosquamous eruptions [<a href="#rid65">65</a>], erythema multiforme-like lesions [<a href="#rid66">66-68</a>], dengue-like rashes [<a href="#rid69">69,70</a>], petechiae [<a href="#rid71">71</a>], and gangrene [<a href="#rid72">72</a>].</p><p>Some infants born to mothers with COVID-19 at birth have had transient rash. In a review of nine small case series from China that included a total of 65 pregnant women who were infected with SARS-CoV-2 during pregnancy and 67 newborns, two newborns presented with a rash [<a href="#rid73">73</a>]. The rash has been described in one infant as a diffuse, maculopapular eruption that resolved in one day with desquamation and in another as a diffuse, red, miliaria-like eruption that disappeared in 10 days without treatment [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H1181096409"><span class="h1">DERMATOLOGIC CONDITIONS RELATED TO THE COVID-19 PANDEMIC</span><span class="headingEndMark"> — </span>Skin injury, mechanical/friction dermatitis, and irritant contact dermatitis due to personal protective equipment (PPE) and hand hygiene measures have been reported in the majority of health care workers involved in the direct care of patients with COVID-19 [<a href="#rid75">75</a>].</p><p class="headingAnchor" id="H2647385021"><span class="h2">Personal protective equipment-induced skin injury</span><span class="headingEndMark"> — </span>Health care workers caring for patients with COVID-19 or patients potentially infected with SARS-CoV-2 may spend long hours wearing PPE. The American Academy of Dermatology has released <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fassets.ctfassets.net%2F1ny4yoiyrqia%2F1evNAmDqSmw6w9dhozuJGZ%2F303efdeff53db6e0347df52c65baf4bc%2FOCC_Derm_Conditions_V11_30Apr2020.pdf&amp;token=dD7KhMux%2BXIx1uDS%2FmUSNRUNOKh4FzIVf105SbowXt3qFRP0hFLlWl18G%2FnM3oijOYpFKasCbGjnHvh%2BsSPdgDDTWEN47A%2FLwdbT740XKC8mwls217T4RN2ZY8YRyGiZEquajePFf6cBDFPuqoSgyYGf4Va3cofO79CJwze3QyAVHmhpOIHEhQFsXvo%2F8OFe&amp;TOPIC_ID=127978" target="_blank">recommendations</a> on preventing and treating occupationally induced dermatologic conditions during the COVID-19 pandemic:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanical injury/friction dermatitis </strong>– PPE-induced skin injury is common, occurring in up to over 90 percent of health care workers [<a href="#rid75">75-78</a>]. Long durations of PPE use (&gt;6 hours per day) increase rates of skin damage [<a href="#rid75">75,76,79</a>]. Masks, goggles, face shields, and gloves apply pressure, create abrasion, and retain moisture and can injure the nasal bridge, cheek, forehead, and hands [<a href="#rid75">75-77</a>]. PPE-induced injuries include desquamation, erythema, maceration, fissuring, papules, and erosions, leading to itching and pain [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Irritant and allergic contact dermatitis</strong> – Multiple case series have reported allergic contact dermatitis due to rubber, adhesives, and formaldehyde, as well as irritant contact dermatitis due to pressure and friction, in health care workers wearing N95 or equivalent masks for &gt;6 hours daily [<a href="#rid80">80,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Facial dermatoses ("maskne")</strong> – New-onset or exacerbation of facial dermatoses, including acne ("maskne"), rosacea ("mask rosacea"), seborrheic dermatitis, periorificial dermatitis, and folliculitis, likely due to friction and occlusion, have been reported in persons wearing masks for &gt;6 hours per day [<a href="#rid80">80,82,83</a>]. Mask-related Koebner phenomenon (trauma-induced development of lesions clinically similar to the underlying skin disease in previously uninvolved areas) has also been described in patients with a variety of skin disorders, including psoriasis, vitiligo, acne, and rosacea [<a href="#rid84">84</a>].</p><p></p><p>Prevention of PPE-related injuries has the potential to reduce PPE protocol breaches due to inadvertent adjustment and touching [<a href="#rid85">85</a>]. The use of barrier films or dressings at pressure points before donning PPE may reduce these types of injuries [<a href="#rid86">86-90</a>]. However, the effects of these preventive measures on PPE ability to prevent viral spread are not well characterized, and caution is warranted [<a href="#rid85">85,88</a>].</p><p class="headingAnchor" id="H1184252125"><span class="h2">Hand hygiene-related dermatitis</span><span class="headingEndMark"> — </span>Hand hygiene is considered a key tool against COVID-19. Hand eczema was already an issue among health care workers and is likely to be an even greater problem with higher rates of hand washing and glove use during the pandemic [<a href="#rid91">91</a>].</p><p>The frequency of irritant contact dermatitis of the hands may be reduced by frequent usage of emollients, washing with lukewarm water instead of hot water, and usage of alcohol-based cleansers when hands are not visibly dirty [<a href="#rid86">86,89,92,93</a>]. Overzealous hand hygiene may cause hand eczema in the general population as well [<a href="#rid94">94</a>].</p><p>The American Academy of Dermatology has released <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fassets.ctfassets.net%2F1ny4yoiyrqia%2F1evNAmDqSmw6w9dhozuJGZ%2F303efdeff53db6e0347df52c65baf4bc%2FOCC_Derm_Conditions_V11_30Apr2020.pdf&amp;token=dD7KhMux%2BXIx1uDS%2FmUSNRUNOKh4FzIVf105SbowXt3qFRP0hFLlWl18G%2FnM3oijOYpFKasCbGjnHvh%2BsSPdgDDTWEN47A%2FLwdbT740XKC8mwls217T4RN2ZY8YRyGiZEquajePFf6cBDFPuqoSgyYGf4Va3cofO79CJwze3QyAVHmhpOIHEhQFsXvo%2F8OFe&amp;TOPIC_ID=127978" target="_blank">recommendations</a> on preventing and treating occupationally induced dermatologic conditions during the COVID-19 pandemic. (See  <a class="medical medical_review" href="/z/d/html/13661.html" rel="external">"Irritant contact dermatitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13658.html" rel="external">"Chronic hand eczema"</a>.)</p><p class="headingAnchor" id="H755180458"><span class="h1">THERAPEUTIC CONSIDERATIONS DURING THE PANDEMIC</span><span class="headingEndMark"> — </span>The COVID-19 pandemic has led to necessary adjustments to the therapeutic approach for some dermatologic diseases. Considerations for immunosuppressive therapy are reviewed here. Various professional organizations have also released guidelines for clinical care during the pandemic. (See <a class="local">'Society guideline links'</a> below and  <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease"</a>.)</p><p class="headingAnchor" id="H2170755119"><span class="h2">Use of biologic and other immunosuppressive therapies</span><span class="headingEndMark"> — </span>Biologic and immunosuppressive therapies play important roles in the management of a wide variety of dermatologic diseases, such as psoriasis, atopic dermatitis, and other inflammatory or autoimmune conditions. The risks of these immunomodulatory therapies in relation to COVID-19 remain unclear. Although it is generally accepted that most patients without COVID-19 who are already taking immunosuppressive drugs for dermatologic disease can continue therapy, a more cautious approach is typically taken for patients who have suspected or confirmed COVID-19 and patients who are considering starting a new immunosuppressive therapy. (See <a class="local">'Patients without COVID-19'</a> below and <a class="local">'Patients with presumed or confirmed COVID-19'</a> below.)</p><p>Recommendations for COVID-19 vaccination in immunocompromised patients are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Immunocompromised individuals'</a>.)</p><p class="headingAnchor" id="H124744180"><span class="h3">Assessment of risk</span><span class="headingEndMark"> — </span>The uncertainty regarding the impact of biologic and other immunosuppressive therapies on SARS-CoV-2 infection risk and COVID-19 severity makes risk assessment challenging [<a href="#rid95">95-97</a>]. Specific challenges for risk assessment include the paucity of data, the various mechanisms of action of immunosuppressive drugs, and the need to consider patient-specific and disease-specific morbidity and comorbidities. Some authors have proposed that the broad immunosuppression induced by small molecule immunosuppressants (eg, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>, <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) may be of greater concern than the targeted immunosuppression induced by biologic drugs; however, the relative safety of individual immunosuppressants remains unclear [<a href="#rid98">98</a>].</p><p>Consideration of the potential risks of immunosuppressive therapy must also be balanced with consideration of the detrimental effects on skin disease and associated conditions that may result from cessation of effective therapies [<a href="#rid99">99</a>]. Cutaneous disease may flare, and occasional patients may not achieve the same level of response upon the reintroduction of a previously effective biologic therapy [<a href="#rid96">96,97</a>]. Of note, the long half-lives of some biologic agents mean that immunosuppressive effects of concern may still persist for some time following the decision to stop therapy.</p><p>Studies evaluating use of immunomodulatory therapies in relation to COVID-19 in patients with dermatologic disease are limited and insufficient for drawing conclusions on risk in this population [<a href="#rid100">100-103</a>]. It is unclear whether data from clinical trials that have assessed risk for upper respiratory infections during biologic therapy for dermatologic disease are applicable to SARS-CoV-2 infection [<a href="#rid97">97,104-106</a>].</p><p>In support of the theory that the risks of continuing biologic therapy for skin disease may be low:</p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective study of 5206 patients in northern Italy treated with biologic agents for plaque psoriasis between February 20 and April 1, 2020, found no COVID-19-related deaths and only four COVID-19-related hospitalizations [<a href="#rid100">100</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A case-control study performed in the Lombardy region of Italy that involved assessment of 1193 patients with psoriasis treated with biologic or small molecule therapy and approximately 10 million controls between February 21 and April 9,<sup> </sup>2020, found higher risks for testing positive for COVID-19, being self-quarantined at home due to COVID-19, or being hospitalized due to COVID-19 among patients with psoriasis receiving biologic therapy compared with controls but did not find statistically significant increases in risk for intensive care unit admission or dying in this population [<a href="#rid101">101</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cohort study that compared outcomes of COVID-19 in 214 patients treated with tumor necrosis factor (TNF) inhibitors or <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> within one year of contracting COVID-19 with over 31,000 patients who did not receive these drugs found no difference in the likelihood of hospitalization or mortality [<a href="#rid107">107</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An international, registry-based study that included patients with psoriasis and confirmed or suspected COVID-19 infection (n = 374) found that patients receiving biologic therapy were less likely to have a COVID-19-related hospitalization than patients receiving nonbiologic systemic therapy [<a href="#rid108">108</a>].</p><p></p><p>Although the potential for a beneficial effect of biologic inhibitors TNF-alpha or interleukin (IL) 17 in COVID-19 has been proposed based upon the theory that some immunosuppressive drugs might have inhibitory effects on damaging immune response that is thought to contribute to organ damage in COVID-19, this has not been proven [<a href="#rid109">109-112</a>]. Data on IL-6 pathway inhibitors is reviewed separately. <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">Dexamethasone</a> has been used in the treatment of select patients with severe COVID-19. (See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Acute course and complications'</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Dexamethasone and other glucocorticoids'</a> and  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'IL-6 pathway inhibitors (eg, tocilizumab)'</a>.)</p><p class="headingAnchor" id="H3622472664"><span class="h3">Patients without COVID-19</span><span class="headingEndMark"> — </span>Decisions on the use of immunosuppressive therapies in patients without signs or symptoms of COVID-19 during the global pandemic should be made on a case-by-case basis and in conjunction with the patient. This may involve review of the patient's comorbidities, severity of the disease originally being treated, limited available data, expert opinion, local recommendations, and patient preference.</p><p class="headingAnchor" id="H4072520429"><span class="h4">Continuation of immunosuppressive therapies</span><span class="headingEndMark"> — </span>Based upon an absence of evidence that suggests benefit of discontinuing immunosuppressive therapies in patients without COVID-19 and the potential detrimental effects of discontinuing effective therapies, the continuation of biologic and small molecule immunosuppressants for dermatologic disease is generally considered a safe and appropriate option for patients who do not have suspected or documented COVID-19 [<a href="#rid113">113-117</a>].</p><p class="headingAnchor" id="H1765886828"><span class="h4">Initiation of immunosuppressive therapies</span><span class="headingEndMark"> — </span>Routine avoidance of initiating a new immunosuppressive therapy for dermatologic disease in patients without COVID-19 is not considered necessary. However, given that some uncertainty remains regarding the effects of immunosuppressive therapies on COVID-19, the decision to start a new immunosuppressive drug for dermatologic disease should be taken carefully, involving a case-specific review of the potential risks and benefits of therapy. In particular, for patients perceived to be at increased risk for severe COVID-19, it may be prudent to consider deferring immunosuppressive treatments in favor of other therapies [<a href="#rid113">113</a>]. (See  <a class="medical medical_review" href="/z/d/html/128323.html" rel="external">"COVID-19: Clinical features", section on 'Risk factors for severe illness'</a>.)</p><p>Some authors have proposed testing for SARS-CoV-2 infection or immunity prior to initiation of immunosuppressive therapies [<a href="#rid118">118</a>]. However, the value of this approach is unclear.</p><p class="headingAnchor" id="H1566995900"><span class="h3">Patients with presumed or confirmed COVID-19</span><span class="headingEndMark"> — </span>Active infection is an accepted indication for discontinuation and avoidance of initiation of immunosuppressive therapies, although this remains an area of debate. This approach may be the appropriate default for most patients with confirmed COVID-19. (See  <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease", section on 'Management of patients with known or suspected SARS-CoV-2 exposure or infection'</a> and <a class="local">'Society guideline links'</a> below.)</p><p>However, given the uncertainty about the effects of various immunosuppressants on the course of COVID-19, the decision to discontinue treatment in a patient with COVID-19 should be made on a case-by-case basis. Other factors that may influence the decision to cease treatment may include the severity of COVID-19 and the potential negative ramifications of treatment cessation on flaring immunologic activity, including both dermatologic disease and comorbidities. (See  <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease"</a>.)</p><p>Immunosuppressive therapy can usually be resumed, if needed, following complete recovery from COVID-19. Guidance the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.psoriasis.org%2Fcovid-19-task-force-guidance-statements%2F&amp;token=KbwHoScDCmu5LpqS%2B%2FdQ4GcWSKXVdH%2FPK4V5yg3%2FXtF%2BRp4roCSBFDP%2BDqTyxTlfoWlKXtKLVSDUEezU23xC4YvqeAfrCGVk6kLNrumIqPs%3D&amp;TOPIC_ID=127978" target="_blank">National Psoriasis Foundation</a> issued in 2022 supports case-by-case shared decision making for the resumption of systemic antipsoriatic therapies in patients with COVID-19 [<a href="#rid114">114</a>].</p><p class="headingAnchor" id="H1471638104"><span class="h2">Skin cancer</span><span class="headingEndMark"> — </span>Issues related to the care of patients with cancer during the pandemic are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/128993.html" rel="external">"COVID-19: Considerations in patients with cancer"</a>.)</p><p class="headingAnchor" id="H2634819657"><span class="h1">CONSIDERATIONS FOR VACCINATION TO PREVENT SARS-COV-2 INFECTION</span><span class="headingEndMark"> — </span>The development of vaccines to prevent SARS-CoV-2 infection occurred at an unprecedented rate. Vaccines to prevent SARS-CoV-2 infection are reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines"</a>.)</p><p class="headingAnchor" id="H516976039"><span class="h2">Cutaneous adverse events</span><span class="headingEndMark"> — </span>Examples of reported cutaneous reactions following receipt of COVID-19 vaccines have included injection site reactions; delayed, large, local reactions (also known as "COVID arm"); urticaria; morbilliform eruptions ("maculopapular rash"); pityriasis rosea-like reactions; pernio/chilblains; bullous pemphigoid-like reactions; lichen planus-like reactions; purpuric reactions; herpes zoster; and other findings [<a href="#rid119">119-126</a>]. Cutaneous and other adverse events following COVID-19 vaccines should be reported. (See <a class="local">'Registries'</a> below.)</p><p>A systematic review and meta-analysis of studies that assessed cutaneous adverse events following COVID-19 vaccination provides additional data on the frequency of cutaneous adverse events [<a href="#rid127">127</a>]. The pooled prevalence of cutaneous manifestations was 3.8 percent (95% CI 2.7-5.3 percent, I<sup>2</sup> = 99.77) among recipients of messenger ribonucleic acid (mRNA)-based vaccines, inactivated SARS-CoV-2 vaccines, or viral vector-based vaccines. Acute, local injection site reactions were the most frequent cutaneous manifestations, accounting for 72 percent of the 44,582 reported cases of vaccine-related cutaneous manifestations. Subgroup analysis also suggested a higher prevalence of cutaneous adverse events in association with mRNA vaccines compared with other vaccine platforms (prevalence of 6.9 percent, 95% CI 3.8-12.3 percent). Limitations of the meta-analysis included high heterogeneity, uncertain causality between vaccination and reported cutaneous outcomes, and incomplete descriptions of cutaneous outcomes in some reports. (See  <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">"COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Reactions to specific vaccines'</a>.)</p><p>Much higher frequencies of injection site reactions reported in some trials reflect the inclusion of "pain" within the category of injection site reactions (ie, cutaneous manifestations not required) [<a href="#rid128">128</a>].</p><p>A grading schema for cutaneous adverse events to COVID-19 vaccines, adapted from the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) drug reaction scale to COVID-19 vaccine reactions, has also been proposed [<a href="#rid129">129</a>].</p><p>Features of some of the most reported cutaneous adverse effects include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Injection site reactions </strong>– Acute injection site reactions are common after vaccination against COVID-19 and other diseases [<a href="#rid126">126,128,130</a>]. Typical symptoms include the development of swelling, erythema, and pain at the vaccination site within one to two days after vaccination. Symptoms usually resolve within several days. Symptomatic treatment can be implemented, when needed. These reactions are not considered contraindications to future vaccination. (See  <a class="medical medical_review" href="/z/d/html/2074.html" rel="external">"Allergic reactions to vaccines", section on 'Delayed vaccine reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed local reactions </strong>– A delayed local reaction secondary to COVID-19 vaccination (also known as "COVID arm") is an immune-mediated reaction characterized by the development of a well-demarcated, inflamed plaque near the site of mRNA vaccination  (<a class="graphic graphic_picture graphicRef130922" href="/z/d/graphic/130922.html" rel="external">picture 3</a>). In contrast to typical injection site reactions, which appear within one to two days after vaccination, the usual time of onset is seven to eight days after vaccination. Delayed local reactions have been most frequently reported following initial vaccination and appear to be more common in females than males [<a href="#rid131">131,132</a>]. Clinically, delayed local reactions may be mistaken for cellulitis. (See  <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">"COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Late local reactions'</a>.)</p><p></p><p class="bulletIndent1">Generally, reactions spontaneously resolve within several days, though longer durations have been reported [<a href="#rid131">131</a>]. Antibiotic therapy is not indicated. Delayed local reactions are not considered contraindications to future COVID-19 vaccination. The approach to subsequent vaccination is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">"COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Late local reactions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Urticaria </strong>– Delayed-onset urticaria after vaccination (eg, urticaria developing more than four hours after vaccination, not part of an anaphylactic reaction) has been reported with the original vaccine series and after booster doses [<a href="#rid121">121,133-138</a>]. In addition, a subset of patients may develop chronic, spontaneous urticaria lasting ≥6 weeks [<a href="#rid139">139,140</a>]. (See  <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">"COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Delayed-onset urticarial reactions'</a> and  <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">"COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Persistent urticaria'</a>.)</p><p></p><p class="bulletIndent1">The approach to treatment of urticaria-associated COVID-19 vaccination resembles the approach to urticaria due to other causes. Antihistamines are the mainstay of treatment. Patients with refractory, chronic, spontaneous urticaria that cannot be controlled with antihistamines alone may benefit from other treatments. Improvement with <a class="drug drug_general" data-topicid="10251" href="/z/d/drug information/10251.html" rel="external">omalizumab</a> after failure of antihistamines is described in a case report [<a href="#rid139">139</a>]. (See  <a class="medical medical_review" href="/z/d/html/8101.html" rel="external">"New-onset urticaria", section on 'Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/8106.html" rel="external">"Chronic spontaneous urticaria: Standard management and patient education", section on 'Stepwise approach to treatment'</a>.)</p><p></p><p class="bulletIndent1">The approach to subsequent COVID-19 vaccination in these patients is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/132246.html" rel="external">"COVID-19: Allergic reactions to SARS-CoV-2 vaccines", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Morbilliform eruptions </strong>– Morbilliform eruptions have been reported after COVID-19 vaccination [<a href="#rid126">126</a>]. The typical clinical findings are widespread, erythematous macules. Associated erythema may be subtle in patients with highly pigmented skin.</p><p></p><p class="bulletIndent1">Morbilliform eruptions usually spontaneously resolve within one to two weeks [<a href="#rid121">121</a>]. Management consists of supportive therapy for associated symptoms (eg, topical corticosteroids, antihistamines). Morbilliform eruptions are not considered contraindications for future vaccination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vaccine-related eruption of papules and plaques </strong>– The term "vaccine-related eruption of papules and plaques" (V-REPP) has been proposed for the group of cutaneous COVID-19 vaccination reactions characterized by the histologic finding of spongiotic dermatitis and clinical findings of papulovesicular (severe V-REPP), pityriasis rosea-like (moderate V-REPP), and papulosquamous skin lesions (mild V-REPP) [<a href="#rid124">124</a>].</p><p></p><p class="bulletIndent1">V-REPP reactions generally appear at least several days after vaccination and may persist for weeks, months, or longer. In one registry-based study that included 15 patients with findings consistent with V-REPP following receipt of an mRNA vaccine, the median time to development of the eruption was 12 days after vaccination, and many patients continued to have active eruptions at the time of reporting [<a href="#rid124">124</a>]. Several patients who developed pityriasis rosea-like lesions after a first dose of an mRNA vaccine experienced a flare after a second dose of the vaccine.</p><p></p><p class="bulletIndent1">Development of V-REPP is not considered a contraindication to future vaccine doses. However, given the possibility of persistent eruptions, shared decision making is important. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Herpes zoster </strong>– A 2022 systematic review of the literature identified 160 reports of patients who developed herpes zoster after COVID-19 vaccination [<a href="#rid126">126</a>]. Although vaccine-related immunomodulation was proposed as a potential mechanism, additional study is necessary to confirm a causative relationship.</p><p></p><p class="headingAnchor" id="H348146033"><span class="h2">Soft tissue fillers</span><span class="headingEndMark"> — </span>Reports of facial swelling following receipt of the mRNA 1273 (Moderna) COVID-19 vaccine in patients with a history of facial soft tissue filler injections suggest a relationship between prior cosmetic soft tissue filler injections and postvaccination swelling, although such reports are rare, and additional data are necessary to confirm an association. A 2022 systematic review identified 16 cases of facial swelling after COVID-19 vaccination in patients with a history of soft tissue fillers and three additional cases following COVID-19 infection [<a href="#rid141">141</a>].</p><p>Given the apparent rarity of this adverse event and the expectation for complete resolution of associated facial swelling, decisions to proceed with soft tissue filler injections in close proximity to receipt of the vaccine may involve consideration of patient and provider tolerance for risk for facial swelling as well as consideration of the risks of delaying COVID-19 vaccination. (See  <a class="medical medical_review" href="/z/d/html/16532.html" rel="external">"Injectable soft tissue fillers: Overview of clinical use"</a>.)</p><p class="headingAnchor" id="H2932226384"><span class="h2">Immunocompromised patients</span><span class="headingEndMark"> — </span>Limited data suggest vaccination against SARS-CoV-2 is safe in dermatologic patients receiving immunomodulatory therapies [<a href="#rid142">142</a>]. Efficacy of vaccination in this population may vary based upon the type of immunomodulatory therapy and vaccine [<a href="#rid142">142</a>]. Guidance regarding administration of COVID-19 vaccines in immunocompromised patients is provided separately. (See  <a class="medical medical_review" href="/z/d/html/129849.html" rel="external">"COVID-19: Vaccines", section on 'Immunocompromised individuals'</a> and  <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease", section on 'COVID-19 vaccination while on immunosuppressive therapy'</a>.)</p><p class="headingAnchor" id="H3828533419"><span class="h1">DELIVERY OF CARE DURING THE PANDEMIC</span><span class="headingEndMark"> — </span>Local guidelines on the performance of medical care during the pandemic differ and continue to evolve. In many settings, the pandemic led to increased use of telemedicine for dermatologic care (ie, teledermatology). In scenarios in which in-person care remains necessary or appropriate, precautions to limit risk for transmission of infection are indicated. (See <a class="local">'Telemedicine'</a> below and <a class="local">'In-person care'</a> below and <a class="local">'Society guideline links'</a> below.)</p><p class="headingAnchor" id="H2907946363"><span class="h2">Telemedicine</span><span class="headingEndMark"> — </span>Telemedicine provides an opportunity to provide care while reducing risk for exposure of clinicians, staff, and patients to individuals with COVID-19 [<a href="#rid143">143,144</a>]. Both synchronous (eg, simultaneous, two-way communication between the patient and clinician via telephone or videoconferencing) and asynchronous (eg, store-and-forward transmission of images for later assessment by the clinician) modalities have been utilized for teledermatology care [<a href="#rid145">145</a>]. A structured triage process may be helpful for identifying patients who require in-person, rather than a telemedicine, visit [<a href="#rid146">146,147</a>]. (See  <a class="medical medical_review" href="/z/d/html/128313.html" rel="external">"Telemedicine for adults"</a>.)</p><p>Telemedicine may also be an appropriate option for inpatient dermatologic care in some scenarios. The Society of Dermatology Hospitalists has produced an algorithm to guide triaging of consultations and the performance of safe inpatient dermatologic care [<a href="#rid148">148</a>].</p><p>Concerns have been raised over privacy and security of telemedicine [<a href="#rid149">149,150</a>]. The platform selected should be compliant with local privacy regulations. Due to the COVID-19 pandemic, some regulatory bodies have relaxed or waived rules to allow more flexibility in telemedicine [<a href="#rid151">151</a>].</p><p>Photography tips for patients seeking telemedicine evaluation for skin conditions are provided in a table  (<a class="graphic graphic_table graphicRef128974" href="/z/d/graphic/128974.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H384682408"><span class="h2">In-person care</span><span class="headingEndMark"> — </span>In-person visits should be performed with appropriate infection control precautions based on current local recommendations and the prevalence of COVID-19 in the local community. (See  <a class="medical medical_review" href="/z/d/html/130296.html" rel="external">"COVID-19: General approach to infection prevention in the health care setting"</a>.)</p><p>Best practices for infection control in the clinical setting are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/127501.html" rel="external">"COVID-19: Infection prevention for persons with SARS-CoV-2 infection", section on 'Infection prevention in the health care setting'</a>.)</p><p class="headingAnchor" id="H3889052848"><span class="h1">REGISTRIES</span></p><p class="headingAnchor" id="H48432769"><span class="h2">COVID-19</span><span class="headingEndMark"> — </span>Multiple registries have been developed, with the goal of increasing knowledge of the dermatologic manifestations and impact of COVID-19 in patients with dermatologic disease. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>General dermatologic manifestations of COVID-19 or patients with COVID-19 and any pre-existing dermatologic condition:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aad.org%2Fmember%2Fpractice%2Fcoronavirus%2Fregistry&amp;token=T2Iknvk5inwR74f3CzLleF%2FoISStRBNhsj07Fc71SdL9TgAyDtQpWYF7%2FNMqq3orBDhYnx%2Be%2B%2Bl0tgh0gIIJCQ%3D%3D&amp;TOPIC_ID=127978" target="_blank">American Academy of Dermatology/International League of Dermatological Societies COVID-19 Registry</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psoriasis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Psoriasis Registry for Outcomes, Therapy, and Epidemiology of COVID-19 Infection (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpsoprotect.org%2F&amp;token=8gyE25tJfWLg%2BJwaBi6aaZRYgph0QfoMyS%2BqKEiLtis%3D&amp;TOPIC_ID=127978" target="_blank">PsoPROTECT</a>)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion Registry (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fschool.wakehealth.edu%2Fdepartments%2Fdermatology%2Fsecure-psoriasis&amp;token=eMJ3TP4gRqcKebrmlc0cOj4eTroL8EoDyQGZ4X4PiljQ%2FhsxeA%2FjJpkTTD4IRBKa6JrB9gRjXPeMFXmEGeCgSXpx7%2FVo17%2FfvepoDETZY%2Fk%3D&amp;TOPIC_ID=127978" target="_blank">SECURE-Psoriasis Registry</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Atopic dermatitis:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion Registry (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.covidderm.org%2Flogin%2F%3Fnext%3D%2Finsight%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlHfDlcEmCTuABsmSuePdHtaZEaJgjZ6J4u%2ByD0Tnir0heOv7UYxgvQcePMLThVujUA%3D%3D&amp;TOPIC_ID=127978" target="_blank">SECURE-AD Registry</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Alopecia:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Surveillance Epidemiology of Coronavirus (COVID-19) Under Research Exclusion Registry (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fsecurealopecia.covidderm.org%2Flogin%2F%3Fnext%3D%2Finsight%2F&amp;token=Xski6MYEClqaGthGM3LjSaChWOi%2BsO2RplNW%2Fdpgqqw%2BdfxJ%2FD%2B4CIQfADfLFt1mHDcUiCfXEYOndKo7ifZpP68AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=127978" target="_blank">SECURE-Alopecia Registry</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hidradenitis suppurativa:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fhscovid.ucsf.edu%2F&amp;token=4JE6vjdLT9tCkv7koAy6Gi6RbSpnPZ0%2FcjwXnfMCJokNGTPqi0iiCXcvm7IL4R5z&amp;TOPIC_ID=127978" target="_blank">Global Hidradenitis Suppurativa COVID-19 Registry</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Acral changes in the pediatric population:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fpedraresearch.org%2F2020%2F04%2F20%2Fcovid-acral-ischemia-perniosis-in-children%2F&amp;token=v1Sz1W2plW53nHWBLwkwd%2By%2FZ5sBX8MND4g%2FXoh9w2TzkPOg4beEgIVPWgY%2FaqPgigVSXvAmmOEBvjpmP132wd76CUKiubnZAs4dC7id1zg%3D&amp;TOPIC_ID=127978" target="_blank">COVID Acral Ischemia/Perniosis in Children Registry</a></p><p></p><p>Disease registries for rheumatologic diseases are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/127933.html" rel="external">"COVID-19: Care of adult patients with systemic rheumatic disease", section on 'Disease registries'</a>.)</p><p class="headingAnchor" id="H3738873261"><span class="h2">COVID-19 vaccine reactions</span><span class="headingEndMark"> — </span>Reactions to COVID-19 vaccines should be reported. Resources for reporting adverse events include:</p><p class="bulletIndent1"><span class="glyph">●</span>All adverse events:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvaers.hhs.gov%2Findex.html&amp;token=8m3rK0tzv73hmwLVujPJP%2FVrZTr5LmKIlDf%2BMKp07YKCkZawMmw76Mlq0N%2Fh3R%2BM&amp;TOPIC_ID=127978" target="_blank">Vaccine Adverse Event Reporting System</a> (The United States Centers for Disease Control and Prevention)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous adverse events:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.aad.org%2Fmember%2Fpractice%2Fcoronavirus%2Fregistry&amp;token=T2Iknvk5inwR74f3CzLleF%2FoISStRBNhsj07Fc71SdL9TgAyDtQpWYF7%2FNMqq3orBDhYnx%2Be%2B%2Bl0tgh0gIIJCQ%3D%3D&amp;TOPIC_ID=127978" target="_blank">COVID-19 Dermatology Registry</a> (American Academy of Dermatology and International League of Dermatologic Societies)</p><p></p><p class="headingAnchor" id="H1333175913"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/126613.html" rel="external">"Society guideline links: COVID-19 – Index of guideline topics"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/130988.html" rel="external">"Society guideline links: COVID-19 – Dermatology care"</a>.)</p><p class="headingAnchor" id="H1122962267"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/126678.html" rel="external">"Patient education: COVID-19 overview (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/130329.html" rel="external">"Patient education: COVID-19 vaccines (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/127544.html" rel="external">"Patient education: COVID-19 and children (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/127758.html" rel="external">"Patient education: COVID-19 and pregnancy (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H378059545"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cutaneous manifestations of COVID-19</strong> – Multiple skin manifestations have been described in patients with confirmed or suspected SARS-CoV-2 infection. These include a morbilliform rash; urticaria; pernio-like, acral lesions; livedo-like, vascular lesions; and vesicular, varicella-like eruptions. A severe multisystem inflammatory syndrome with mucocutaneous, systemic, laboratory, and imaging findings of atypical, severe Kawasaki disease has also been reported in children and adolescents with COVID-19. (See <a class="local">'Cutaneous manifestations of COVID-19'</a> above and  <a class="medical medical_review" href="/z/d/html/128190.html" rel="external">"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Personal protective equipment and hand hygiene-related dermatoses</strong> – Skin injury, mechanical/friction dermatitis, and hand irritant contact dermatitis due to personal protective equipment (PPE) and hand hygiene measures have been reported in the majority of health care workers involved in the care of patients with COVID-19. Use of barrier films or dressings at pressure points of PPE and frequent use of emollients after hand washing may help reduce skin damage and irritation. (See <a class="local">'Dermatologic conditions related to the COVID-19 pandemic'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of the pandemic on dermatologic care</strong> – The COVID-19 pandemic has contributed to the need to adjust aspects of dermatologic care. Examples include adjustments in the approach to immunosuppressive treatment, phototherapy, skin cancer treatment, and routine clinical care (see <a class="local">'Therapeutic considerations during the pandemic'</a> above and <a class="local">'Delivery of care during the pandemic'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Immunosuppressive therapy</strong> – The impact of immunosuppressive therapies for dermatologic disease on risk for SARS-CoV-2 infection and risk for complications of COVID-19 is unclear. The decision to continue or start immunosuppressive therapy for dermatologic disease during the pandemic should be made on a case-by-case basis. Examples of important factors to consider include the patient's infection status, the immunosuppressant under consideration, and the impact of treatment cessation on the dermatologic disease and comorbidities (see <a class="local">'Therapeutic considerations during the pandemic'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients without COVID-19</strong> – Given the absence of evidence indicating benefit of discontinuing immunosuppressive therapies in patients without COVID-19, continuation of immunosuppressive therapy for dermatologic disease is considered a safe and appropriate option for this population. The decision to start a new immunosuppressive drug should include careful consideration of potential risks and benefits of therapy. For patients with risk for severe COVID-19, it may be appropriate to defer immunosuppressive treatments in favor of other therapies. (See <a class="local">'Patients without COVID-19'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Patients with COVID-19</strong> – Active infection is an accepted indication for discontinuation of immunosuppressive therapies. However, the decision to continue, discontinue, or resume immunosuppressive treatment in patients with presumed or confirmed COVID-19 should be made on a case-by-case basis. (See <a class="local">'Patients with presumed or confirmed COVID-19'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Delivery of care</strong> – The COVID-19 pandemic has contributed to increased use of telemedicine for routine clinical care. When in-person visits are performed, appropriate infection control precautions should be implemented. (See <a class="local">'Delivery of care during the pandemic'</a> above and  <a class="medical medical_review" href="/z/d/html/130296.html" rel="external">"COVID-19: General approach to infection prevention in the health care setting"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Freeman EE, McMahon DE. Creating dermatology guidelines for COVID-19: The pitfalls of applying evidence-based medicine to an emerging infectious disease. J Am Acad Dermatol 2020; 82:e231.</a></li><li><a class="nounderline abstract_t">Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183:71.</a></li><li><a class="nounderline abstract_t">de Masson A, Bouaziz JD, Sulimovic L, et al. Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France. J Am Acad Dermatol 2020; 83:667.</a></li><li><a class="nounderline abstract_t">Freeman EE, McMahon DE, Lipoff JB, et al. Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries. J Am Acad Dermatol 2020; 83:486.</a></li><li><a class="nounderline abstract_t">Daneshgaran G, Dubin DP, Gould DJ. Cutaneous Manifestations of COVID-19: An Evidence-Based Review. Am J Clin Dermatol 2020; 21:627.</a></li><li><a class="nounderline abstract_t">Tan SW, Tam YC, Oh CC. Skin manifestations of COVID-19: A worldwide review. JAAD Int 2021; 2:119.</a></li><li><a class="nounderline abstract_t">Marzano AV, Genovese G, Moltrasio C, et al. The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients. J Am Acad Dermatol 2021; 84:1356.</a></li><li><a class="nounderline abstract_t">Recalcati S, Gianotti R, Fantini F. COVID-19: The experience from Italy. Clin Dermatol 2021; 39:12.</a></li><li><a class="nounderline abstract_t">Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382:1708.</a></li><li><a class="nounderline abstract_t">Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34:e212.</a></li><li><a class="nounderline abstract_t">Madigan LM, Micheletti RG, Shinkai K. How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic. JAMA Dermatol 2020; 156:733.</a></li><li><a class="nounderline abstract_t">Rajan M B, Kumar-M P, Bhardwaj A. The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review. Int J Dermatol 2020; 59:1358.</a></li><li><a class="nounderline abstract_t">Visconti A, Bataille V, Rossi N, et al. Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection. Br J Dermatol 2021; 184:880.</a></li><li><a class="nounderline abstract_t">Mascitti H, Jourdain P, Bleibtreu A, et al. Prognosis of rash and chilblain-like lesions among outpatients with COVID-19: a large cohort study. Eur J Clin Microbiol Infect Dis 2021; 40:2243.</a></li><li><a class="nounderline abstract_t">Visconti A, Murray B, Rossi N, et al. Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app. Br J Dermatol 2022; 187:900.</a></li><li><a class="nounderline abstract_t">Sugai T, Fujita Y, Inamura E, et al. Prevalence and patterns of cutaneous manifestations in 1245 COVID-19 patients in Japan: a single-centre study. J Eur Acad Dermatol Venereol 2022; 36:e522.</a></li><li><a class="nounderline abstract_t">Sameni F, Hajikhani B, Yaslianifard S, et al. COVID-19 and Skin Manifestations: An Overview of Case Reports/Case Series and Meta-Analysis of Prevalence Studies. Front Med (Lausanne) 2020; 7:573188.</a></li><li><a class="nounderline abstract_t">Freeman EE, McMahon DE, Fitzgerald ME, et al. The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19. J Am Acad Dermatol 2020; 83:509.</a></li><li><a class="nounderline abstract_t">Freeman EE, McMahon DE, Lipoff JB, et al. The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries. J Am Acad Dermatol 2020; 83:1118.</a></li><li><a class="nounderline abstract_t">Najarian DJ. Morbilliform exanthem associated with COVID-19. JAAD Case Rep 2020; 6:493.</a></li><li><a class="nounderline abstract_t">Sachdeva M, Gianotti R, Shah M, et al. Cutaneous manifestations of COVID-19: Report of three cases and a review of literature. J Dermatol Sci 2020; 98:75.</a></li><li><a class="nounderline abstract_t">McCleskey PE, Zimmerman B, Lieberman A, et al. Epidemiologic Analysis of Chilblains Cohorts Before and During the COVID-19 Pandemic. JAMA Dermatol 2021; 157:947.</a></li><li><a class="nounderline abstract_t">Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol 2020; 83:e61.</a></li><li><a class="nounderline abstract_t">Bouaziz JD, Duong TA, Jachiet M, et al. Vascular skin symptoms in COVID-19: a French observational study. J Eur Acad Dermatol Venereol 2020; 34:e451.</a></li><li><a class="nounderline abstract_t">Alramthan A, Aldaraji W. Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East. Clin Exp Dermatol 2020; 45:746.</a></li><li><a class="nounderline abstract_t">Andina D, Noguera-Morel L, Bascuas-Arribas M, et al. Chilblains in children in the setting of COVID-19 pandemic. Pediatr Dermatol 2020; 37:406.</a></li><li><a class="nounderline abstract_t">Colonna C, Monzani NA, Rocchi A, et al. Chilblain-like lesions in children following suspected COVID-19 infection. Pediatr Dermatol 2020; 37:437.</a></li><li><a class="nounderline abstract_t">Recalcati S, Barbagallo T, Frasin LA, et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol 2020; 34:e346.</a></li><li><a class="nounderline abstract_t">Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, et al. Comment on "Characterization of acute acro-ischemic lesions in non-hospitalized patients: A case series of 132 patients during the COVID-19 outbreak". J Am Acad Dermatol 2020; 83:e241.</a></li><li><a class="nounderline abstract_t">Guarneri C, Venanzi Rullo E, Gallizzi R, et al. Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19. J Eur Acad Dermatol Venereol 2020; 34:e449.</a></li><li><a class="nounderline abstract_t">Le Cleach L, Dousset L, Assier H, et al. Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing. Br J Dermatol 2020; 183:866.</a></li><li><a class="nounderline abstract_t">Freeman EE, McMahon DE, Hruza GJ, et al. Timing of PCR and antibody testing in patients with COVID-19-associated dermatologic manifestations. J Am Acad Dermatol 2021; 84:505.</a></li><li><a class="nounderline abstract_t">Balestri R, Magnano M, Rizzoli L, Rech G. Do we have serological evidences that chilblain-like lesions are related to SARS-CoV-2? A review of the literature. Dermatol Ther 2020; 33:e14229.</a></li><li><a class="nounderline abstract_t">Diociaiuti A, Giancristoforo S, Terreri S, et al. Are SARS-CoV-2 IgA antibodies in paediatric patients with chilblain-like lesions indicative of COVID-19 asymptomatic or paucisymptomatic infection? J Eur Acad Dermatol Venereol 2021; 35:e10.</a></li><li><a class="nounderline abstract_t">Hubiche T, Le Duff F, Chiaverini C, et al. Negative SARS-CoV-2 PCR in patients with chilblain-like lesions. Lancet Infect Dis 2021; 21:315.</a></li><li><a class="nounderline abstract_t">Gehlhausen JR, Little AJ, Ko CJ, et al. Lack of association between pandemic chilblains and SARS-CoV-2 infection. Proc Natl Acad Sci U S A 2022; 119.</a></li><li><a class="nounderline abstract_t">Frumholtz L, Bouaziz JD, Battistella M, et al. Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak. Br J Dermatol 2021; 185:1176.</a></li><li><a class="nounderline abstract_t">Lee DS, Mirmirani P, McCleskey PE, et al. Cutaneous manifestations of COVID-19: a systematic review and analysis of individual patient-level data. Dermatol Online J 2020; 26.</a></li><li><a class="nounderline abstract_t">Rekhtman S, Tannenbaum R, Strunk A, et al. Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19. J Am Acad Dermatol 2021; 84:946.</a></li><li><a class="nounderline abstract_t">McMahon DE, Gallman AE, Hruza GJ, et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis 2021; 21:313.</a></li><li><a class="nounderline abstract_t">Discepolo V, Catzola A, Pierri L, et al. Bilateral Chilblain-like Lesions of the Toes Characterized by Microvascular Remodeling in Adolescents During the COVID-19 Pandemic. JAMA Netw Open 2021; 4:e2111369.</a></li><li><a class="nounderline abstract_t">Freeman EE, McMahon DE, Lipoff JB, et al. Cold and COVID: recurrent pernio during the COVID-19 pandemic. Br J Dermatol 2021; 185:214.</a></li><li><a class="nounderline abstract_t">Zhang Y, Cao W, Xiao M, et al. [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia]. Zhonghua Xue Ye Xue Za Zhi 2020; 41:E006.</a></li><li><a class="nounderline abstract_t">Gianotti R, Recalcati S, Fantini F, et al. Histopathological Study of a Broad Spectrum of Skin Dermatoses in Patients Affected or Highly Suspected of Infection by COVID-19 in the Northern Part of Italy: Analysis of the Many Faces of the Viral-Induced Skin Diseases in Previous and New Reported Cases. Am J Dermatopathol 2020; 42:564.</a></li><li><a class="nounderline abstract_t">Kanitakis J, Lesort C, Danset M, Jullien D. Chilblain-like acral lesions during the COVID-19 pandemic ("COVID toes"): Histologic, immunofluorescence, and immunohistochemical study of 17 cases. J Am Acad Dermatol 2020; 83:870.</a></li><li><a class="nounderline abstract_t">Colmenero I, Santonja C, Alonso-Riaño M, et al. SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases. Br J Dermatol 2020; 183:729.</a></li><li><a class="nounderline abstract_t">Hubiche T, Cardot-Leccia N, Le Duff F, et al. Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic. JAMA Dermatol 2021; 157:202.</a></li><li><a class="nounderline abstract_t">Docampo-Simón A, Sánchez-Pujol MJ, Juan-Carpena G, et al. Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review. J Eur Acad Dermatol Venereol 2020; 34:e445.</a></li><li><a class="nounderline abstract_t">Herman A, Peeters C, Verroken A, et al. Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic. JAMA Dermatol 2020; 156:998.</a></li><li><a class="nounderline abstract_t">Roca-Ginés J, Torres-Navarro I, Sánchez-Arráez J, et al. Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic. JAMA Dermatol 2020; 156:992.</a></li><li><a class="nounderline abstract_t">Thomas C. Reply to: "A dermatologic manifestation of COVID-19: Transient livedo reticularis". J Am Acad Dermatol 2020; 83:e155.</a></li><li><a class="nounderline abstract_t">Manalo IF, Smith MK, Cheeley J, Jacobs R. A dermatologic manifestation of COVID-19: Transient livedo reticularis. J Am Acad Dermatol 2020; 83:700.</a></li><li><a class="nounderline abstract_t">Verheyden M, Grosber M, Gutermuth J, Velkeniers B. Relapsing symmetric livedo reticularis in a patient with COVID-19 infection. J Eur Acad Dermatol Venereol 2020; 34:e684.</a></li><li><a class="nounderline abstract_t">Marzano AV, Cassano N, Genovese G, et al. Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue. Br J Dermatol 2020; 183:431.</a></li><li><a class="nounderline abstract_t">Matar S, Oulès B, Sohier P, et al. Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature. J Eur Acad Dermatol Venereol 2020; 34:e686.</a></li><li><a class="nounderline abstract_t">Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res 2020; 220:1.</a></li><li><a class="nounderline abstract_t">Llamas-Velasco M, Muñoz-Hernández P, Lázaro-González J, et al. Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19. Br J Dermatol 2020; 183:591.</a></li><li><a class="nounderline abstract_t">Quintana-Castanedo L, Feito-Rodríguez M, Valero-López I, et al. Urticarial exanthem as early diagnostic clue for COVID-19 infection. JAAD Case Rep 2020; 6:498.</a></li><li><a class="nounderline abstract_t">Marzano AV, Genovese G, Fabbrocini G, et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients. J Am Acad Dermatol 2020; 83:280.</a></li><li><a class="nounderline abstract_t">Ortega-Quijano D, Jimenez-Cauhe J, Burgos-Blasco P, et al. Reply to "Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients": Discussing specificity. J Am Acad Dermatol 2020; 83:e87.</a></li><li><a class="nounderline abstract_t">Fernandez-Nieto D, Ortega-Quijano D, Jimenez-Cauhe J, et al. Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital. Clin Exp Dermatol 2020; 45:872.</a></li><li><a class="nounderline abstract_t">Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020; 395:1771.</a></li><li><a class="nounderline abstract_t">Riphagen S, Gomez X, Gonzalez-Martinez C, et al. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 2020; 395:1607.</a></li><li><a class="nounderline abstract_t">Young TK, Shaw KS, Shah JK, et al. Mucocutaneous Manifestations of Multisystem Inflammatory Syndrome in Children During the COVID-19 Pandemic. JAMA Dermatol 2021; 157:207.</a></li><li><a class="nounderline abstract_t">Sanchez A, Sohier P, Benghanem S, et al. Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA Dermatol 2020; 156:819.</a></li><li><a class="nounderline abstract_t">Jimenez-Cauhe J, Ortega-Quijano D, Carretero-Barrio I, et al. Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings. Clin Exp Dermatol 2020; 45:892.</a></li><li><a class="nounderline abstract_t">Janah H, Zinebi A, Elbenaye J. Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2. J Eur Acad Dermatol Venereol 2020; 34:e373.</a></li><li><a class="nounderline abstract_t">Torrelo A, Andina D, Santonja C, et al. Erythema multiforme-like lesions in children and COVID-19. Pediatr Dermatol 2020; 37:442.</a></li><li><a class="nounderline abstract_t">Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020; 82:e177.</a></li><li><a class="nounderline abstract_t">Jimenez-Cauhe J, Ortega-Quijano D, Prieto-Barrios M, et al. Reply to "COVID-19 can present with a rash and be mistaken for dengue": Petechial rash in a patient with COVID-19 infection. J Am Acad Dermatol 2020; 83:e141.</a></li><li><a class="nounderline abstract_t">Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A, et al. Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. JAMA Dermatol 2020; 156:820.</a></li><li><a class="nounderline abstract_t">Ma J, Xia P, Zhou Y, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19. Clin Immunol 2020; 214:108408.</a></li><li><a class="nounderline abstract_t">Zimmermann P, Curtis N. COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features. Pediatr Infect Dis J 2020; 39:469.</a></li><li><a class="nounderline abstract_t">Chen Y, Peng H, Wang L, et al. Infants Born to Mothers With a New Coronavirus (COVID-19). Front Pediatr 2020; 8:104.</a></li><li><a class="nounderline abstract_t">Lin P, Zhu S, Huang Y, et al. Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions. Br J Dermatol 2020; 183:190.</a></li><li><a class="nounderline abstract_t">Lan J, Song Z, Miao X, et al. Skin damage among health care workers managing coronavirus disease-2019. J Am Acad Dermatol 2020; 82:1215.</a></li><li><a class="nounderline abstract_t">Jiang Q, Song S, Zhou J, et al. The Prevalence, Characteristics, and Prevention Status of Skin Injury Caused by Personal Protective Equipment Among Medical Staff in Fighting COVID-19: A Multicenter, Cross-Sectional Study. Adv Wound Care (New Rochelle) 2020; 9:357.</a></li><li><a class="nounderline abstract_t">Daye M, Cihan FG, Durduran Y. Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID-19 pandemic. Dermatol Ther 2020; 33:e14346.</a></li><li><a class="nounderline abstract_t">Battista RA, Ferraro M, Piccioni LO, et al. Personal Protective Equipment (PPE) in COVID 19 Pandemic: Related Symptoms and Adverse Reactions in Healthcare Workers and General Population. J Occup Environ Med 2021; 63:e80.</a></li><li><a class="nounderline abstract_t">Yu J, Chen JK, Mowad CM, et al. Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review. J Am Acad Dermatol 2021; 84:486.</a></li><li><a class="nounderline abstract_t">Techasatian L, Lebsing S, Uppala R, et al. The Effects of the Face Mask on the Skin Underneath: A Prospective Survey During the COVID-19 Pandemic. J Prim Care Community Health 2020; 11:2150132720966167.</a></li><li><a class="nounderline abstract_t">Rudd E, Walsh S. Mask related acne ("maskne") and other facial dermatoses. BMJ 2021; 373:n1304.</a></li><li><a class="nounderline abstract_t">Damiani G, Gironi LC, Grada A, et al. COVID-19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi-center, real-life, telemedical, and observational prospective study. Dermatol Ther 2021; 34:e14848.</a></li><li><a class="nounderline abstract_t">Damiani G, Gironi LC, Kridin K, et al. Mask-induced Koebner phenomenon and its clinical phenotypes: A multicenter, real-life study focusing on 873 dermatological consultations during COVID-19 pandemics. Dermatol Ther 2021; 34:e14823.</a></li><li><a class="nounderline abstract_t">Kantor J. Behavioral considerations and impact on personal protective equipment use: Early lessons from the coronavirus (COVID-19) pandemic. J Am Acad Dermatol 2020; 82:1087.</a></li><li><a class="nounderline abstract_t">Yan Y, Chen H, Chen L, et al. Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019. Dermatol Ther 2020; 33:e13310.</a></li><li><a class="nounderline abstract_t">Elston DM. Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic. J Am Acad Dermatol 2020; 82:1085.</a></li><li><a class="nounderline abstract_t">Oranges T, Janowska A, Dini V. Reply to: "Skin damage among health care workers managing coronavirus disease-2019". J Am Acad Dermatol 2020; 82:e233.</a></li><li><a class="nounderline abstract_t">Balato A, Ayala F, Bruze M, et al. European Task Force on Contact Dermatitis statement on coronavirus disease-19 (COVID-19) outbreak and the risk of adverse cutaneous reactions. J Eur Acad Dermatol Venereol 2020; 34:e353.</a></li><li><a class="nounderline abstract_t">Desai SR, Kovarik C, Brod B, et al. COVID-19 and personal protective equipment: Treatment and prevention of skin conditions related to the occupational use of personal protective equipment. J Am Acad Dermatol 2020; 83:675.</a></li><li><a class="nounderline abstract_t">Patruno C, Fabbrocini G, Stingeni L, Napolitano M. The role of occupational dermatology in the COVID-19 outbreak. Contact Dermatitis 2020; 83:174.</a></li><li><a class="nounderline abstract_t">Abtahi-Naeini B. Frequent handwashing amidst the COVID-19 outbreak: prevention of hand irritant contact dermatitis and other considerations. Health Sci Rep 2020; 3:e163.</a></li><li><a class="nounderline abstract_t">Cavanagh G, Wambier CG. Rational hand hygiene during the coronavirus 2019 (COVID-19) pandemic. J Am Acad Dermatol 2020; 82:e211.</a></li><li><a class="nounderline abstract_t">Singh M, Pawar M, Bothra A, Choudhary N. Overzealous hand hygiene during the COVID 19 pandemic causing an increased incidence of hand eczema among general population. J Am Acad Dermatol 2020; 83:e37.</a></li><li><a class="nounderline abstract_t">Conforti C, Giuffrida R, Dianzani C, et al. COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther 2020; 33:e13298.</a></li><li><a class="nounderline abstract_t">Bashyam AM, Feldman SR. Should patients stop their biologic treatment during the COVID-19 pandemic. J Dermatolog Treat 2020; 31:317.</a></li><li><a class="nounderline abstract_t">Lebwohl M, Rivera-Oyola R, Murrell DF. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol 2020; 82:1217.</a></li><li><a class="nounderline abstract_t">Price KN, Frew JW, Hsiao JL, Shi VY. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol 2020; 82:e173.</a></li><li><a class="nounderline abstract_t">Coletto LA, Favalli EG, Caporali R. Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days. Dermatol Ther 2020; 33:e13415.</a></li><li><a class="nounderline abstract_t">Gisondi P, Facheris P, Dapavo P, et al. The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience. Br J Dermatol 2020; 183:373.</a></li><li><a class="nounderline abstract_t">Damiani G, Pacifico A, Bragazzi NL, Malagoli P. Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration. Dermatol Ther 2020; 33:e13475.</a></li><li><a class="nounderline abstract_t">Carugno A, Raponi F, Locatelli AG, et al. No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy. J Eur Acad Dermatol Venereol 2020; 34:e433.</a></li><li><a class="nounderline abstract_t">Holcomb ZE, Santillan MR, Morss-Walton PC, et al. Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy. J Am Acad Dermatol 2020; 83:1215.</a></li><li><a class="nounderline abstract_t">Brownstone ND, Thibodeaux QG, Reddy VD, et al. Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times. Dermatol Ther (Heidelb) 2020; 10:339.</a></li><li><a class="nounderline abstract_t">Blaszczak A, Trinidad JCL, Cartron AM. Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations. J Am Acad Dermatol 2020; 83:e31.</a></li><li><a class="nounderline abstract_t">Wan MT, Shin DB, Winthrop KL, Gelfand JM. The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. J Am Acad Dermatol 2020; 83:677.</a></li><li><a class="nounderline abstract_t">Yousaf A, Gayam S, Feldman S, et al. Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study. J Am Acad Dermatol 2021; 84:70.</a></li><li><a class="nounderline abstract_t">Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol 2021; 147:60.</a></li><li><a class="nounderline abstract_t">Tobinick E. TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection. Curr Med Res Opin 2004; 20:39.</a></li><li><a class="nounderline abstract_t">Hussell T, Pennycook A, Openshaw PJ. Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol 2001; 31:2566.</a></li><li><a class="nounderline abstract_t">Zumla A, Hui DS, Azhar EI, et al. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 2020; 395:e35.</a></li><li><a class="nounderline abstract_t">Pacha O, Sallman MA, Evans SE. COVID-19: a case for inhibiting IL-17? Nat Rev Immunol 2020; 20:345.</a></li><li class="breakAll">Guidance on the use of biologic agents during COVID-19 outbreak. American Academy of Dermatology. https://assets.ctfassets.net/1ny4yoiyrqia/PicgNuD0IpYd9MSOwab47/07b614658aff5fc6ccc4c0bd910509a3/Biologics_and_COVID_19_FINAL_V2.pdf (Accessed on May 07, 2020).</li><li class="breakAll">National Psoriasis Foundation Medical Board COVID-19 Task Force Guidance Statements https://www.psoriasis.org/covid-19-task-force-guidance-statements/ (Accessed on December 16, 2022).</li><li class="breakAll">International Psoriasis Council Statement on the Coronavirus (COVID-19) Outbreak. www.psoriasiscouncil.org/blog/Statement-on-COVID-19-and-Psoriasis.htm (Accessed on May 07, 2020).</li><li class="breakAll">Dermatology Advice Regarding Self-Isolation and Immunosuppressed Patients: Adults, Paediatrics and Young People. British Association of Dermatologists. www.bad.org.uk/healthcare-professionals/covid-19/covid-19-immunosuppressed-patients (Accessed on May 07, 2020).</li><li class="breakAll">Guidance on the Use of Systemic Therapy for Patients with Psoriasis/Atopic Dermatitis During the Covid-19 (Sars-Cov-2, Coronavirus) Pandemic (April 2020). International League of Dermatological Societies. https://ilds.org/covid-19/guidance-psoriasis-atopic-dermatitis/ (Accessed on May 07, 2020).</li><li><a class="nounderline abstract_t">Alpalhão M, Filipe P. Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link? J Dermatolog Treat 2020; 31:439.</a></li><li><a class="nounderline abstract_t">Rice SM, Ferree SD, Mesinkovska NA, Kourosh AS. The art of prevention: COVID-19 vaccine preparedness for the dermatologist. Int J Womens Dermatol 2021; 7:209.</a></li><li><a class="nounderline abstract_t">Blumenthal KG, Freeman EE, Saff RR, et al. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2. N Engl J Med 2021; 384:1273.</a></li><li><a class="nounderline abstract_t">McMahon DE, Amerson E, Rosenbach M, et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. J Am Acad Dermatol 2021; 85:46.</a></li><li><a class="nounderline abstract_t">Català A, Muñoz-Santos C, Galván-Casas C, et al. Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases. Br J Dermatol 2022; 186:142.</a></li><li><a class="nounderline abstract_t">Meara AS, Silkowski M, Quin K, Jarjour W. A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine? J Rheumatol 2021; 48:1754.</a></li><li><a class="nounderline abstract_t">McMahon DE, Kovarik CL, Damsky W, et al. Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study. J Am Acad Dermatol 2022; 86:113.</a></li><li><a class="nounderline abstract_t">Duperrex O, Tommasini F, Muller YD. Incidence of Chronic Spontaneous Urticaria Following Receipt of the COVID-19 Vaccine Booster in Switzerland. JAMA Netw Open 2023; 6:e2254298.</a></li><li><a class="nounderline abstract_t">Avallone G, Quaglino P, Cavallo F, et al. SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review. Int J Dermatol 2022; 61:1187.</a></li><li><a class="nounderline abstract_t">Washrawirul C, Triwatcharikorn J, Phannajit J, et al. Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2022; 36:1947.</a></li><li><a class="nounderline abstract_t">Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021; 384:403.</a></li><li><a class="nounderline abstract_t">Singh R, Ali R, Prasad S, et al. Proposing a standardized assessment of COVID-19 vaccine-associated cutaneous reactions. J Am Acad Dermatol 2023; 88:237.</a></li><li><a class="nounderline abstract_t">Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. Front Immunol 2021; 12:714170.</a></li><li><a class="nounderline abstract_t">Johnston MS, Galan A, Watsky KL, Little AJ. Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series. JAMA Dermatol 2021; 157:716.</a></li><li><a class="nounderline abstract_t">Fernandez-Nieto D, Hammerle J, Fernandez-Escribano M, et al. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization. J Eur Acad Dermatol Venereol 2021; 35:e425.</a></li><li><a class="nounderline abstract_t">Kroumpouzos G, Paroikaki ME, Yumeen S, et al. Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review. Microorganisms 2022; 10.</a></li><li><a class="nounderline abstract_t">Pitlick MM, Joshi AY, Gonzalez-Estrada A, Chiarella SE. Delayed systemic urticarial reactions following mRNA COVID-19 vaccination. Allergy Asthma Proc 2022; 43:40.</a></li><li><a class="nounderline abstract_t">Wolfson AR, Freeman EE, Blumenthal KG. Urticaria 12 Days After COVID-19 mRNA Booster Vaccination. JAMA 2022; 327:1702.</a></li><li><a class="nounderline abstract_t">Prasad S, McMahon DE, Tyagi A, et al. Cutaneous reactions following booster dose administration of COVID-19 mRNA vaccine: A first look from the American Academy of Dermatology/International League of Dermatologic Societies registry. JAAD Int 2022; 8:49.</a></li><li><a class="nounderline abstract_t">Anvari S, Samarakoon U, Fu X, et al. Urticaria and/or angioedema secondary to mRNA COVID-19 vaccines: Updates from a United States case registry. Allergy 2023; 78:283.</a></li><li><a class="nounderline abstract_t">Judd A, Samarakoon U, Wolfson AR, et al. Urticaria after COVID-19 vaccination and vaccine hesitancy. J Allergy Clin Immunol Pract 2023; 11:958.</a></li><li><a class="nounderline abstract_t">Strahan A, Ali R, Freeman EE. Chronic spontaneous urticaria after COVID-19 primary vaccine series and boosters. JAAD Case Rep 2022; 25:63.</a></li><li><a class="nounderline abstract_t">Suan D, Lee AYS. Chronic spontaneous urticaria following ChAdOx1-S COVID-19 vaccination. Allergo J Int 2022; 31:121.</a></li><li><a class="nounderline abstract_t">Bachour Y, Bekkenk MW, Rustemeyer T, Kadouch JA. Late inflammatory reactions in patients with soft tissue fillers after SARS-CoV-2 infection and vaccination: A systematic review of the literature. J Cosmet Dermatol 2022; 21:1361.</a></li><li><a class="nounderline abstract_t">Gresham LM, Marzario B, Dutz J, Kirchhof MG. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology. J Am Acad Dermatol 2021; 84:1652.</a></li><li><a class="nounderline abstract_t">Villani A, Scalvenzi M, Fabbrocini G. Teledermatology: a useful tool to fight COVID-19. J Dermatolog Treat 2020; 31:325.</a></li><li><a class="nounderline abstract_t">Gupta R, Ibraheim MK, Doan HQ. Teledermatology in the wake of COVID-19: Advantages and challenges to continued care in a time of disarray. J Am Acad Dermatol 2020; 83:168.</a></li><li><a class="nounderline abstract_t">Armstrong AW, Chambers CJ, Maverakis E, et al. Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial. JAMA Netw Open 2018; 1:e183062.</a></li><li><a class="nounderline abstract_t">Price KN, Thiede R, Shi VY, Curiel-Lewandrowski C. Strategic dermatology clinical operations during the coronavirus disease 2019 (COVID-19) pandemic. J Am Acad Dermatol 2020; 82:e207.</a></li><li><a class="nounderline abstract_t">Gisondi P, Piaserico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol 2020; 34:1196.</a></li><li><a class="nounderline abstract_t">Trinidad J, Kroshinsky D, Kaffenberger BH, Rojek NW. Telemedicine for inpatient dermatology consultations in response to the COVID-19 pandemic. J Am Acad Dermatol 2020; 83:e69.</a></li><li><a class="nounderline abstract_t">Jakhar D, Kaul S, Kaur I. WhatsApp messenger as a teledermatology tool during coronavirus disease (COVID-19): from bedside to phone-side. Clin Exp Dermatol 2020; 45:739.</a></li><li><a class="nounderline abstract_t">Black SM, Ali FR. Secure communication conduits during COVID-19 lockdown. Clin Exp Dermatol 2020; 45:748.</a></li><li><a class="nounderline abstract_t">Lee I, Kovarik C, Tejasvi T, et al. Telehealth: Helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation. J Am Acad Dermatol 2020; 82:1213.</a></li></ol></div><div id="topicVersionRevision">Topic 127978 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32278795" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Creating dermatology guidelines for COVID-19: The pitfalls of applying evidence-based medicine to an emerging infectious disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32348545" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32380219" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32479979" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32865778" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Cutaneous Manifestations of COVID-19: An Evidence-Based Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33479703" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Skin manifestations of COVID-19: A worldwide review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33476725" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The clinical spectrum of COVID-19-associated cutaneous manifestations: An Italian multicenter study of 200 adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33972039" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : COVID-19: The experience from Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32109013" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical Characteristics of Coronavirus Disease 2019 in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32215952" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cutaneous manifestations in COVID-19: a first perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32352485" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32936462" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The trend of cutaneous lesions during COVID-19 pandemic: lessons from a meta-analysis and systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33448030" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diagnostic value of cutaneous manifestation of SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34255231" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Prognosis of rash and chilblain-like lesions among outpatients with COVID-19: a large cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35869671" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Cutaneous manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348 691 UK users of the UK ZOE COVID Study app.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35274364" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence and patterns of cutaneous manifestations in 1245 COVID-19 patients in Japan: a single-centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33224961" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : COVID-19 and Skin Manifestations: An Overview of Case Reports/Case Series and Meta-Analysis of Prevalence Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305438" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32622888" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32313826" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Morbilliform exanthem associated with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32381430" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Cutaneous manifestations of COVID-19: Report of three cases and a review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34160569" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Epidemiologic Analysis of Chilblains Cohorts Before and During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339703" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339344" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Vascular skin symptoms in COVID-19: a French observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32302422" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Two cases of COVID-19 presenting with a clinical picture resembling chilblains: first report from the Middle East.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32386460" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Chilblains in children in the setting of COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32374033" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chilblain-like lesions in children following suspected COVID-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32330324" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Acral cutaneous lesions in the time of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32497704" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Comment on "Characterization of acute acro-ischemic lesions in non-hospitalized patients: A case series of 132 patients during the COVID-19 outbreak".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32441830" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Diversity of clinical appearance of cutaneous manifestations in the course of COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32628270" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Most chilblains observed during the COVID-19 outbreak occur in patients who are negative for COVID-19 on polymerase chain reaction and serology testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32920037" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Timing of PCR and antibody testing in patients with COVID-19-associated dermatologic manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32844512" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Do we have serological evidences that chilblain-like lesions are related to SARS-CoV-2? A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32920919" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Are SARS-CoV-2 IgA antibodies in paediatric patients with chilblain-like lesions indicative of COVID-19 asymptomatic or paucisymptomatic infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32563281" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Negative SARS-CoV-2 PCR in patients with chilblain-like lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35217624" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lack of association between pandemic chilblains and SARS-CoV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34611893" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33423412" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cutaneous manifestations of COVID-19: a systematic review and analysis of individual patient-level data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33359476" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33460566" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Long COVID in the skin: a registry analysis of COVID-19 dermatological duration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34110396" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Bilateral Chilblain-like Lesions of the Toes Characterized by Microvascular Remodeling in Adolescents During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33657646" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cold and COVID: recurrent pernio during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32220276" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : [Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32701690" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Histopathological Study of a Broad Spectrum of Skin Dermatoses in Patients Affected or Highly Suspected of Infection by COVID-19 in the Northern Part of Italy: Analysis of the Many Faces of the Viral-Induced Skin Diseases in Previous and New Reported Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32502585" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Chilblain-like acral lesions during the COVID-19 pandemic ("COVID toes"): Histologic, immunofluorescence, and immunohistochemical study of 17 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32562567" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : SARS-CoV-2 endothelial infection causes COVID-19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33237291" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical, Laboratory, and Interferon-Alpha Response Characteristics of Patients With Chilblain-like Lesions During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32452545" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Are chilblain-like acral skin lesions really indicative of COVID-19? A prospective study and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584377" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evaluation of Chilblains as a Manifestation of the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32584397" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Assessment of Acute Acral Lesions in a Case Series of Children and Adolescents During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32387666" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reply to: "A dermatologic manifestation of COVID-19: Transient livedo reticularis".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283229" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A dermatologic manifestation of COVID-19: Transient livedo reticularis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32588475" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Relapsing symmetric livedo reticularis in a patient with COVID-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32479680" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cutaneous manifestations in patients with COVID-19: a preliminary review of an emerging issue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32589293" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Cutaneous manifestations in SARS-CoV-2 infection (COVID-19): a French experience and a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32299776" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32407552" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Thrombotic occlusive vasculopathy in a skin biopsy from a livedoid lesion of a patient with COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32352022" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Urticarial exanthem as early diagnostic clue for COVID-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305439" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32380215" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Reply to "Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients": Discussing specificity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32384180" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Clinical and histological characterization of vesicular COVID-19 rashes: a prospective study in a tertiary care hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32410760" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32386565" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hyperinflammatory shock in children during COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33295957" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Mucocutaneous Manifestations of Multisystem Inflammatory Syndrome in Children During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32352486" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Digitate Papulosquamous Eruption Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32385858" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Erythema multiforme-like eruption in patients with COVID-19 infection: clinical and histological findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32386446" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Atypical erythema multiforme palmar plaques lesions due to Sars-Cov-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32445583" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Erythema multiforme-like lesions in children and COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32213305" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : COVID-19 can present with a rash and be mistaken for dengue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283233" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Reply to "COVID-19 can present with a rash and be mistaken for dengue": Petechial rash in a patient with COVID-19 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32352487" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Petechial Skin Rash Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32247038" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32398569" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : COVID-19 in Children, Pregnancy and Neonates: A Review of Epidemiologic and Clinical Features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32266184" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Infants Born to Mothers With a New Coronavirus (COVID-19).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32255197" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171808" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Skin damage among health care workers managing coronavirus disease-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320359" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The Prevalence, Characteristics, and Prevention Status of Skin Injury Caused by Personal Protective Equipment Among Medical Staff in Fighting COVID-19: A Multicenter, Cross-Sectional Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32985745" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Evaluation of skin problems and dermatology life quality index in health care workers who use personal protection measures during COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33298757" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Personal Protective Equipment (PPE) in COVID 19 Pandemic: Related Symptoms and Adverse Reactions in Healthcare Workers and General Population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33011325" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33084483" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : The Effects of the Face Mask on the Skin Underneath: A Prospective Survey During the COVID-19 Pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34099456" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Mask related acne ("maskne") and other facial dermatoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33533563" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : COVID-19 related masks increase severity of both acne (maskne) and rosacea (mask rosacea): Multi-center, real-life, telemedical, and observational prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33527560" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Mask-induced Koebner phenomenon and its clinical phenotypes: A multicenter, real-life study focusing on 873 dermatological consultations during COVID-19 pandemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171806" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Behavioral considerations and impact on personal protective equipment use: Early lessons from the coronavirus (COVID-19) pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32170800" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Consensus of Chinese experts on protection of skin and mucous membrane barrier for health-care workers fighting against coronavirus disease 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32171807" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283228" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Reply to: "Skin damage among health care workers managing coronavirus disease-2019".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356382" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : European Task Force on Contact Dermatitis statement on coronavirus disease-19 (COVID-19) outbreak and the risk of adverse cutaneous reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32416206" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : COVID-19 and personal protective equipment: Treatment and prevention of skin conditions related to the occupational use of personal protective equipment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32319103" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : The role of occupational dermatology in the COVID-19 outbreak.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32346616" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Frequent handwashing amidst the COVID-19 outbreak: prevention of hand irritant contact dermatitis and other considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32268168" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Rational hand hygiene during the coronavirus 2019 (COVID-19) pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32305441" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Overzealous hand hygiene during the COVID 19 pandemic causing an increased incidence of hand eczema among general population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32157783" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191143" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Should patients stop their biologic treatment during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32199889" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Should biologics for psoriasis be interrupted in the era of COVID-19?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32224277" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : COVID-19 and immunomodulator/immunosuppressant use in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32291828" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32343839" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32356577" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339362" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : No evidence of increased risk for Coronavirus Disease 2019 (COVID-19) in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32622141" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Risk of COVID-19 in dermatologic patients receiving long-term immunomodulatory therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32300516" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32283230" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32416207" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32926977" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33075408" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14741070" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : TNF-alpha inhibition for potential therapeutic modulation of SARS coronavirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11536154" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32035018" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Reducing mortality from 2019-nCoV: host-directed therapies should be an option.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358580" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : COVID-19: a case for inhibiting IL-17?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358580" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : COVID-19: a case for inhibiting IL-17?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358580" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : COVID-19: a case for inhibiting IL-17?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358580" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : COVID-19: a case for inhibiting IL-17?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358580" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : COVID-19: a case for inhibiting IL-17?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32358580" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : COVID-19: a case for inhibiting IL-17?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32323591" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Immunomodulators and immunosuppressants in the era of SARS-CoV-2 - could laboratory tests be the missing link?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33457487" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : The art of prevention: COVID-19 vaccine preparedness for the dermatologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33657292" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33838206" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34254291" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34210829" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A Case of Chilblains-like Lesions Post SARS-CoV-2 Vaccine?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34517079" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36723944" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Incidence of Chronic Spontaneous Urticaria Following Receipt of the COVID-19 Vaccine Booster in Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35141881" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35666609" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33378609" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35569593" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Proposing a standardized assessment of COVID-19 vaccine-associated cutaneous reactions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34707602" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33978670" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Delayed Localized Hypersensitivity Reactions to the Moderna COVID-19 Vaccine: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33783873" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35336199" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34983709" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Delayed systemic urticarial reactions following mRNA COVID-19 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35420647" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Urticaria 12 Days After COVID-19 mRNA Booster Vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35498758" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Cutaneous reactions following booster dose administration of COVID-19 mRNA vaccine: A first look from the American Academy of Dermatology/International League of Dermatologic Societies registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35842747" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Urticaria and/or angioedema secondary to mRNA COVID-19 vaccines: Updates from a United States case registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36581074" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Urticaria after COVID-19 vaccination and vaccine hesitancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35637698" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Chronic spontaneous urticaria after COVID-19 primary vaccine series and boosters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35284208" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Chronic spontaneous urticaria following ChAdOx1-S COVID-19 vaccination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35150192" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Late inflammatory reactions in patients with soft tissue fillers after SARS-CoV-2 infection and vaccination: A systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33482251" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32238000" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Teledermatology: a useful tool to fight COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32334056" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Teledermatology in the wake of COVID-19: Advantages and challenges to continued care in a time of disarray.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30646223" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Effectiveness of Online vs In-Person Care for Adults With Psoriasis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32277972" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Strategic dermatology clinical operations during the coronavirus disease 2019 (COVID-19) pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320091" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Dermatologists and SARS-CoV-2: the impact of the pandemic on daily practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32339708" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Telemedicine for inpatient dermatology consultations in response to the COVID-19 pandemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243612" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : WhatsApp messenger as a teledermatology tool during coronavirus disease (COVID-19): from bedside to phone-side.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32302418" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Secure communication conduits during COVID-19 lockdown.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32229278" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Telehealth: Helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
